Evidence map›Paper›PMID 34111761›Full record

ArticleJournal of the neurological sciences2021

Use of coffee grounds to test olfaction for predicting cognitive dysfunction and decline.

Alexander J Rajic, Peter S Pressman, Jonathan H Woodcock, Heidi J Chial, Christopher M Filley

Open access · greenAbstract read
In one paragraph

Article in Journal of the neurological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alexander J RajicUniversity of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America.
Peter S PressmanUniversity of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Behavioral Neurology Section, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America. Electronic address: peter.pressman@cuanschutz.edu.
Jonathan H WoodcockUniversity of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Behavioral Neurology Section, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America.
Heidi J ChialUniversity of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Linda Crnic Institute for Down Syndrome, 12700 E. 19th Ave., Mail Stop 8608, Aurora, CO 80045, United States of America.
Christopher M FilleyUniversity of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Department of Psychiatry, 13001 East 17(th) Place, Q20-C2000, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Behavioral Neurology Section, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Marcus Institute for Brain Health, 12348 E Montview Blvd., Aurora, CO 80045, United States of America.
University of Colorado Anschutz Medical Campus · US

Funding

Computational Speech Analysis in Alzheimer's Disease and Other Neurocognitive Disorders (Supplement)K23AG063900 · NIA · UNIVERSITY OF COLORADO DENVER · PI PRESSMAN, PETER SCOTT · 2020 to 2024
$980k
NIA NIH HHS K23 AG063900
6 · The paper itself

Abstract

introductionOur objective was to determine whether non-standardized testing of olfaction may provide useful information for predicting cognitive dysfunction and decline in patients with neurobehavioral disorders.

methodsWe conducted cross-sectional and longitudinal analyses of 82 patients who presented to a Memory Clinic with a chief complaint of cognitive deficits using non-standardized odor identification testing (nSOIT). Each patient was classified as having intact or impaired olfaction based on the ability to identify and name the odor of coffee grounds. The cross-sectional study used Student's t-test to examine whether nSOIT results were related to cognitive dysfunction as approximated by Montreal Cognitive Assessment (MoCA) scores. The longitudinal study used mixed effects multiple regression with an interaction term to investigate whether nSOIT results were predictive of cognitive decline over a period of follow-up testing (0.4 to 4.0 years [mean 1.4, SD 0.8]) to compare patients who exhibited cognitive decline over the evaluation period (decliners) and those who did not (non-decliners).

resultsAnalysis of the initial use of nSOIT in the cross-sectional study demonstrated no association between nSOIT performance and objective cognitive dysfunction. In the longitudinal study, impairment in follow-up nSOIT testing was found to be a sensitive but nonspecific predictor of cognitive decline.

conclusionThese results suggest that routine olfactory testing may serve as a convenient and readily available method that can be used by clinicians to better predict cognitive dysfunction and decline in patients with a variety of neurobehavioral disorders.

Indexed as

Cognitive DysfunctionOlfaction DisordersCoffeeCross-Sectional StudiesHumansLongitudinal StudiesNeuropsychological TestsSmellCoffeeDementiaOlfaction

Identifiers

PMID34111761
PMCPMC8916057
OpenAlexW3170846801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.